治疗模式,存活率和成本效益的回顾性队列分析,下奥地利复发/阻断性扩散性大B细胞淋巴瘤 (2018-2022) 的治疗模式,存活率和成本效益 (2018-2022)
Josef Singer1,2, Sandra Gottsauner-Wolf3, Doris A Behrens4,5,6
1Karl Landsteiner University of Health Sciences, Krems, Austria.
Cancer medicine
|February 24, 2026
概括
现代免疫疗法显著提高了复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 患者的生存率,但成本昂贵. 评估现实世界的治疗暴露,而不仅仅是日历时期,准确地反映了这些好处和经济影响.
科学领域:
- 在瘤学瘤学.
- 药物经济学 药物经济学
- 现实世界的证据.
背景情况:
- 复发性/耐药性扩散性大B细胞淋巴瘤 (r/r DLBCL) 具有侵略性,治疗选择有限.
- 新型免疫疗法在临床试验中显示出前景,但实际的有效性和成本尚不清楚.
- 新型疗法的高成本给医疗保健系统带来了挑战.
研究的目的:
- 评估可用于r/r DLBCL的现实世界疗法的疗效和成本.
- 为了比较不同的回顾性分析方法来评估新疗法.
主要方法:
- 追溯分析比较基于日历的队列 (Polatuzumab-vedotin在EMA批准之前和之后).
- 追溯分析根据实际治疗暴露对患者进行分组 (现代与传统疗法).
- 评估整体存活率 (OS) 和相关的医疗保健费用.
主要成果:
- 基于日历的比较由于重叠的治疗周期,只能提供有限的见解.
- 根据治疗暴露分组显示,使用现代疗法显著改善了存活率 (中位数存活20个月与5个月).
- 现代疗法与更高的成本相关 (178,513欧元与15,185欧元),每增加一个生命月的增量成本为10,889欧元.
结论:
- 现代疗法显著提高了r/rDLBCL的生存率,但需要进行成本效益分析以实现最佳整合.
- 根据实际治疗暴露对患者进行分组,可以比基于日历的比较更准确地评估临床益处和经济影响.
- 需要协调努力,以确保公平获得新型治疗方法,同时保持医疗保健的可持续性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...